Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Bayer AG    BAYN   DE000BAY0017

BAYER AG

(BAYN)
  Report
Delayed Quote. Delayed Xetra - 02/20 11:35:15 am
74.66 EUR   -1.09%
02/19Covestro sees lower earnings, weaker volume growth in 'challenging' 2020
RE
02/18GRAIN HIGHLIGHTS : Top Stories of the Day
DJ
02/18LIVESTOCK HIGHLIGHTS : Top Stories of the Day
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Bayer Roundup cancer trial postponed to continue settlement talks

share with twitter share with LinkedIn share with facebook
share via e-mail
01/24/2020 | 03:04pm EST

Bayer AG said on Friday it has reached an agreement with plaintiffs' lawyers to postpone a Missouri jury trial over allegations its popular weed killer Roundup causes cancer to provide room for negotiations to settle the litigation.

"While Bayer is constructively engaged in the mediation process, there is no comprehensive agreement at this time. There also is no certainty or timetable for a comprehensive resolution," the company said in a statement in reference to the settlement talks.

The fourth jury trial in the Roundup litigation was scheduled to begin in St. Louis on Friday morning, but never got underway as lawyers for the company and the cancer patients sat down to discuss a hold of the trial.

The lawsuit would have marked the first multi-plaintiff trial over whether glyphosate, Roundup's active ingredient, is carcinogenic, and the first trial outside of California. St. Louis is the hometown of Roundup-maker Monsanto, a unit Bayer acquired in a $63 billion (48 billion pounds) deal in 2018.

Three consecutive juries previously found the company liable for causing cancer with damages of tens of millions of dollars awarded to each plaintiff. Bayer is appealing those verdicts.

Court-appointed mediator Ken Feinberg, who leads the settlement discussions, has put the number of Roundup cancer claimants at more than 75,000 while Bayer said the claims it has been served with in court were below 50,000.

Bayer on Friday said it will continue the mediation process under Feinberg in good faith.

By Tina Bellon

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BAYER AG
02/19Covestro sees lower earnings, weaker volume growth in 'challenging' 2020
RE
02/18GRAIN HIGHLIGHTS : Top Stories of the Day
DJ
02/18LIVESTOCK HIGHLIGHTS : Top Stories of the Day
DJ
02/17NEWS HIGHLIGHTS : Top Company News of the Day
DJ
02/17NEWS HIGHLIGHTS : Top Company News of the Day
DJ
02/17NEWS HIGHLIGHTS : Top Company News of the Day
DJ
02/17NEWS HIGHLIGHTS : Top Company News of the Day
DJ
02/17EUROPE : China measures, Italian banks lift European shares to record close
RE
02/17NEWS HIGHLIGHTS : Top Company News of the Day
DJ
02/17GLOBAL MARKETS LIVE: Washington will not facilitate the rise of a Chinese pla..
More news
Financials (EUR)
Sales 2019 43 985 M
EBIT 2019 7 863 M
Net income 2019 3 104 M
Debt 2019 35 722 M
Yield 2019 3,82%
P/E ratio 2019 24,5x
P/E ratio 2020 15,8x
EV / Sales2019 2,48x
EV / Sales2020 2,30x
Capitalization 73 348 M
Chart BAYER AG
Duration : Period :
Bayer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 82,43  €
Last Close Price 74,66  €
Spread / Highest target 64,7%
Spread / Average Target 10,4%
Spread / Lowest Target -48,1%
EPS Revisions
Managers
NameTitle
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Wolfgang U. Nickl Chief Financial Officer
Katharina Jansen Head-Science & Research
Florian Schwalbach Head-Information Technology & Business Services
Sector and Competitors
1st jan.Capitalization (M$)
BAYER AG2.54%80 053
JOHNSON & JOHNSON2.24%392 415
ROCHE HOLDING AG10.05%303 192
NOVARTIS3.81%220 641
MERCK AND COMPANY-9.84%208 771
PFIZER-7.30%200 501